Information Regarding Clinical Trial

Title	Part 1 Run In for first 15 patients "A Phase II, multicenter, randomized, two-arm study of Capmatinib (INC280, an oral MET inhibitor) combination therapy vs docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic NSCLC"
Protocol Number	CINC280D2201
Sponsor	Novartis
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	Part 1: Run In for first 15 patients Must be stage IIIB or IV, EGFR and ALK neg, prior platinum- based chemotherapy and PD L1 inhibitor therapy with PD L1 to be last drug given, must have at least 1 measurable lesion (Recist 1.1). Part 1 will treat with Capmatinib and Spartalizumab combination. Review will take place after all subjects have at least 24 wks of follow up before start of Part 2.